For Immediate Release
Chicago, IL – April 22, 2010 – Zacks highlights commentary from People and Picks Trader “MackTheKnife”.
For more Voice of the People, visit http://at.zacks.com/?id=5851
Featured Post
DNDN Presents Data on Provenge MOA
IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) clinical-trial data showing evidence of immune responses in patients treated with Provenge and supporting its proposed mechanism of action were presented by the Dendreon Corp. (DNDN) at the American Association for Cancer Research’s 101st Annual Meeting, which began Saturday and ends today in Washington.
The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1 to Dendreon’s amended biologics license application for Provenge, which the company is seeking to have licensed for men with metastatic castrate-resistant prostate cancer (CRPC). Should the FDA follow the data this time around, Provenge would be the first product in the new therapeutic class known as active cellular immunotherapies.
In a press release today, David Urdal, senior vice president and chief scientific officer of Dendreon, notes: “These data strongly support our understanding of the proposed mechanism of action of active cellular immunotherapies. There is clear evidence that Provenge primes the T-cell component of the immune system in vivo through ex vivo activation, generating a successful and long-lasting immune response.”
About the Zacks Community
In 2008, Zacks Investment Research launched PeopleAndPicks.com, a stock-picking website where members of the Zacks community can test their strategies and share ideas with other members. Each user is scored on the accuracy of his or her picks, and top users are rewarded with free products from Zacks. Registration is free. To learn more about People And Picks, visit http://at.zacks.com/?id=5957
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3:1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit From the Pros by going to http://at.zacks.com/?id=5958.
Follow us on Twitter: http://twitter.com/ZacksInvestment
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact: Brent Billock
People & Picks Manager
Company: Zacks.com
Phone: 312-265-9307
Email: pandp@zacks.com
Visit: www.Zacks.com
